Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | MELK | Q14680 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19962886 | 1.00 | NR3C1 (0.34) | NR3C1ADORA2AADORA2BADORA1CRHR1 | |
| SCHEMBL19962884 | 1.00 | NR3C1 (0.34) | NR3C1ADORA2AADORA2BADORA1CRHR1 | |
| SCHEMBL19962945 | 0.92 | NR3C1 (0.35) | NR3C1ADORA2AADORA2BADORA1CRHR1 | |
| SCHEMBL19962922 | 0.91 | NR3C1 (0.34) | NR3C1ADORA2AADORA2BADORA1CRHR1 | |
| SCHEMBL19962887 | 0.88 | RIPK2 (0.34) | NR3C1ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL19962921 | 0.88 | RIPK2 (0.34) | NR3C1ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL19962883 | 0.86 | MELK (0.40) | NR3C1ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL19962888 | 0.83 | MELK (0.37) | ADORA2AADORA2BADORA1ADORA3MELK | |
| SCHEMBL19962885 | 0.82 | MELK (0.40) | ADORA2AADORA2BADORA1ADORA3MELK | |
| SCHEMBL19951563 | 0.82 | MELK (0.42) | ADORA2AADORA2BADORA1ADORA3MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339142-B2 | Di-substituted pyrazole compounds for the treatment of diseases | FGH BIOTECH, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2020132700-A1 | METHODS OF USING INHIBITORS OF SREBP IN COMBINATION WITH NICLOSAMIDE AND ANALOGS THEREOF | Fgh Biotech Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20190194167-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2018049080-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339142-B2 | Di-substituted pyrazole compounds for the treatment of diseases | SREBF1, SREBF2, CYP27A1 | NR3C1 1014/4885ADORA2A 3796/4885ADORA2B 4331/4885 |
| US-20190194167-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | SREBF1, SREBF2, CYP27A1 | NR3C1 1014/4885ADORA2A 3796/4885ADORA2B 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.